#pharmaceutical-investment

#pharmaceutical-investment

London's position as Europe's leading clinical research hub generates profound impacts extending far beyond laboratory walls and hospital wards. Hundreds of London trials running simultaneously create a sophisticated ecosystem connecting pharmaceutical companies, research institutions, healthcare providers, and most importantly, thousands of patients seeking access to innovative treatments whilst contributing to medical advancement. This ecosystem delivers tangible economic value whilst simultaneously addressing patient needs that conventional healthcare often cannot meet.

Patrick Vallance, a former executive at drugmaker GSK, said the country needed to increase spending on medicines and reverse a decade of declining investment. We are determined to solve this, Lord Vallance told the Commons science committee. This is not something [where] we're sitting saying let's watch the decline of the industry. That's what's happened for the past 10 years. We must not do that. We have to act. Now is a pivotal moment to try to get this right.

We've still got the best universities, we've got some of the best scientists in the world, but it's not a good place to do the development work for medicines. It's an expensive place to operate, and it's a terrible place to sell medicines.